Advanced search    

Search: authors:"Shouhao Zhou"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Comprehensive Investigation on Controlling for CT Imaging Variabilities in Radiomics Studies

Shouhao Zhou, Rick R. Layman, A. Kyle Jones, Clifton D. Fuller, Rebecca M. Howell, Heng Li, R. Jason Stafford, Laurence E. Court & Dennis S. MackinDepartment of Biostatistics, The University of Texas MD ... AuthorsSearch for Rachel B. Ger in:Nature Research journals • PubMed • Google Scholar Search for Shouhao Zhou in:Nature Research journals • PubMed • Google Scholar Search for Pai-Chun Melinda Chi in:Nature

Erratum: Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers

, Rachel B. Ger, Abdallah S.R. Mohamed, Musaddiq J. Awan, Yao Ding 6 Petra J. van Houdt , Renjie He, Shouhao Zhou, Kelsey B. Mathieu, Heng Li, Catherine Coolens 7 Kimberly Li , Xenia J. Fave, Andrew L. Beers

Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been correlated with prognosis in head and neck squamous cell carcinoma as well as with changes in normal tissues. These studies implement different software, either commercial or in-house, and different scan protocols. Thus, the generalizability of the results is not confirmed. To assist in the standardization of...

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints

Background Antibody therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule 4 (CTLA-4) and programmed cell death 1 (PD-1) has demonstrated marked tumor regression in clinical trials. MicroRNAs (miRNAs) can modulate multiple gene transcripts including possibly more than one immune checkpoint and could be exploited as immune therapeutics.

PD-L1 expression and prognostic impact in glioblastoma

Background Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At...